Now Available!
Provocholine® Inhalation Solution
Methapharm Respiratory is excited to introduce our new Provocholine product, the only FDA approved ready-to-use methacholine chloride solution for the methacholine challenge test. This sterile solution is used to assess airway hyperresponsiveness, a key clinical feature of asthma. Provocholine Solution is indicated in adults and children 5 years of age and older when asthma suspected.
Same globally trusted product in a new convenient formulation.
Ready-to-Use Premixed Kit
For the Methacholine Challenge Test
Sterile
Stored at room temperature
Single patient kit – no waste
Colour-coded concentrations avoids errors
Dosing protocol recommended in ATS/ERS guidelines (quadrupling)
Ready-to-Use Premixed Kit
For the Methacholine Challenge Test
Sterile
Stored at room temperature
Single patient kit – no waste
Colour-coded concentrations avoids errors
Dosing protocol recommended in ATS/ERS guidelines (quadrupling)
Product Information
Kit Components (Doses)
Diluent
3 mL
0.0625 mg/mL
(0.1875 mg/3 mL)
0.25 mg/mL
(0.75 mg/3 mL)
1 mg/mL
(3 mg/3 mL)
4 mg/mL
(12 mg/3 mL)
16 mg/mL
(48 mg/3 mL)
Product Insert
Reimbursement
Nebulizer Characterization
WARNING: SEVERE BRONCHOCONSTRICTION
Severe bronchoconstriction can result from Provocholine administration (including the lowest dose). The use of Provocholine is contraindicated in pediatric and adult patients with baseline FEV1 < 60% predicted or adults with FEV1 < 1.5 L. Because of the potential for severe bronchoconstriction, the use of Provocholine in patients with clinically apparent asthma or wheezing is not recommended [see Warnings and Precautions]. Emergency equipment and medication should be immediately available to treat acute respiratory distress. If severe bronchoconstriction occurs, reverse immediately with a rapid-acting inhaled bronchodilator agent (β-agonist) [see Warnings and Precautions]. If baseline spirometry is not performed or is measured inaccurately, the initial FEV1 may be underestimated. In this situation, decreases in FEV1 may not be detected after administration of escalating Provocholine doses, which may result in administration of unnecessary higher doses and an increased risk for excessive bronchoconstriction [see Warnings and Precautions – Section 5 of the Prescribing Information].